MolDX: Predictive Classifiers for Early Stage Non-Small Cell Lung Cancer

Molecular classifier testing for early-stage non-squamous NSCLC (AJCC 8th edition stage I–IIa) is covered when the patient is a candidate for adjuvant platinum-containing chemotherapy, is sufficiently healthy to tolerate chemotherapy, and the test is ordered by the treating clinician (typically a medical oncologist, surgeon, or radiation oncologist) to inform the adjuvant chemotherapy decision. No additional documentation, frequency limits, or explicit exclusions were specified in the provided policy text.

"Patient has non-squamous non-small cell lung cancer (NSCLC) corresponding to American Joint Committee on Cancer (AJCC) 8th edition stage I or stage IIa."

Sign up to see full coverage criteria, indications, and limitations.